Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-Assisted Therapy for Depression
NCT07582120Phase 2Not yet recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2026
- Primary completion
- Jun 2031
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), sponsored by Washington University School of Medicine. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07582120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07582120.